Salarius Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-14.18 Insider Own0.90% Shs Outstand2.25M Perf Week3.63%
Market Cap4.64M Forward P/E- EPS next Y-4.89 Insider Trans0.00% Shs Float2.17M Perf Month-7.41%
Income-29.30M PEG- EPS next Q-2.15 Inst Own16.30% Short Float / Ratio5.80% / 0.71 Perf Quarter66.67%
Sales0.00M P/S- EPS this Y37.90% Inst Trans-6.68% Short Interest0.13M Perf Half Y-57.78%
Book/sh7.39 P/B0.28 EPS next Y34.30% ROA-90.50% Target Price70.50 Perf Year-80.49%
Cash/sh7.53 P/C0.28 EPS next 5Y- ROE-98.10% 52W Range1.07 - 11.10 Perf YTD30.72%
Dividend- P/FCF- EPS past 5Y- ROI-33.10% 52W High-81.98% Beta0.97
Dividend %- Quick Ratio5.80 Sales past 5Y12.70% Gross Margin- 52W Low86.92% ATR0.16
Employees16 Current Ratio5.80 Sales Q/Q- Oper. Margin- RSI (14)43.55 Volatility8.85% 6.39%
OptionableNo Debt/Eq0.00 EPS Q/Q-207.40% Profit Margin- Rel Volume0.06 Prev Close2.08
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume178.09K Price2.00
Recom1.00 SMA20-4.13% SMA50-12.50% SMA200-42.70% Volume6,173 Change-3.85%
Apr-27-20Initiated Ladenburg Thalmann Buy $3.80
Mar-27-23 08:30AM
Mar-15-23 11:00AM
Mar-07-23 08:00AM
Feb-16-23 08:30AM
Jan-27-23 08:30AM
08:30AM Loading…
Jan-19-23 08:30AM
Jan-05-23 08:00AM
Dec-13-22 08:01AM
Dec-08-22 08:00AM
Dec-01-22 08:00AM
Nov-10-22 08:30AM
Nov-03-22 09:57AM
Oct-27-22 08:30AM
Oct-19-22 08:30AM
08:30AM Loading…
Oct-18-22 08:30AM
Oct-14-22 08:43AM
Sep-20-22 12:00PM
Sep-13-22 08:00AM
Aug-22-22 08:30AM
Aug-08-22 08:30AM
Aug-04-22 08:30AM
Aug-02-22 08:30AM
Jul-29-22 09:15AM
Jun-09-22 07:33AM
May-18-22 04:10PM
May-12-22 04:05PM
May-11-22 04:05PM
May-05-22 07:30AM
Apr-22-22 08:30AM
04:05PM Loading…
Mar-10-22 04:05PM
Mar-03-22 07:31AM
Feb-17-22 08:01AM
Feb-15-22 09:00AM
Feb-08-22 08:00AM
Feb-03-22 07:30AM
Jan-14-22 01:52PM
Jan-13-22 07:00AM
Jan-06-22 12:45PM
Dec-29-21 08:03AM
Dec-20-21 08:35AM
Dec-15-21 08:31AM
Dec-14-21 08:35AM
Nov-29-21 08:01AM
Nov-04-21 04:05PM
Oct-28-21 03:06PM
Oct-26-21 08:01AM
Oct-07-21 09:05AM
Oct-05-21 08:01AM
Sep-30-21 04:35PM
Sep-28-21 07:01AM
Sep-27-21 08:03AM
Sep-22-21 07:33AM
Sep-20-21 08:35AM
Sep-15-21 08:03AM
Sep-10-21 08:35AM
Sep-08-21 08:13AM
Aug-12-21 02:00PM
Aug-10-21 06:16AM
Aug-05-21 07:32AM
Jul-29-21 07:33AM
Jul-14-21 08:05AM
Jul-13-21 07:33AM
Jul-09-21 07:33AM
Jun-17-21 08:03AM
Jun-15-21 07:30AM
Jun-10-21 01:30PM
Jun-07-21 07:35AM
May-19-21 05:01PM
May-12-21 04:05PM
May-05-21 07:05AM
Apr-29-21 07:30AM
Apr-19-21 07:30AM
Mar-18-21 04:05PM
Mar-11-21 04:15PM
Mar-08-21 04:05PM
Mar-04-21 08:30AM
Mar-03-21 04:05PM
Feb-24-21 07:00AM
Feb-22-21 07:30AM
Feb-17-21 09:00AM
Feb-16-21 07:30AM
Feb-10-21 06:21AM
Jan-21-21 08:05AM
Jan-15-21 07:30AM
Jan-13-21 07:30AM
Dec-22-20 07:30AM
Dec-11-20 11:32AM
Dec-10-20 09:28AM
Nov-17-20 07:30AM
Nov-11-20 04:05PM
Nov-04-20 07:30AM
Oct-13-20 07:30AM
Sep-21-20 08:35AM
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lieber Jonathan IDirectorJun 07Buy0.1937,5007,01637,500Jun 08 03:12 PM
Burleson TessDirectorJun 07Buy0.1827,7004,98632,050Jun 08 03:14 PM
McVicar William K.DirectorJun 06Buy0.1926,5535,00026,553Jun 07 04:33 PM
HANISH ARNOLD CDirectorJun 03Buy0.1828,0005,15246,350Jun 06 08:33 PM
Rosenblum Mark JExec VP Finance, CFOMay 31Buy0.1828,0005,040148,319May 31 05:13 PM
Arthur David J.Chief Executive OfficerMay 26Buy0.1822,0003,997281,674May 31 05:17 PM
Arthur David J.Chief Executive OfficerMay 26Buy0.1821,9003,987303,574May 31 05:17 PM